|Bid||0.1740 x 900|
|Ask||0.1847 x 1400|
|Day's range||0.1720 - 0.1857|
|52-week range||0.1300 - 1.1000|
|Beta (5Y monthly)||0.42|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
KemPharm (KMPH) inks deal to acquire Orphazyme A/S, which will add to its portfolio the latter's pipeline candidate, arimoclomol, being developed for treating Niemann-Pick disease type C. Shares rise.
The FDA accepts Regulus' (RGLS) IND application for RGLS8429 to treat autosomal dominant polycystic kidney disease. The company plans to begin a phase I study in second-quarter 2022. Stock up.
Catalyst's (CPRX) first-quarter 2022 earnings miss estimates while revenues meet the same.